On September 28, 2026, Shanghai-based MOYOM Biotech announced an investment from the Cathay Consumer Co-Creation Fund. The amount was not disclosed. According to the company release, the proceeds will support clinical translation, additional regulatory approvals, overseas expansion, and development of next-generation regenerative biomaterials.
This was not concept-stage financing. Company disclosures state that MOYOM's Aphranel product received Class III medical-device registration in China in February 2025, entered the market in May 2025, and obtained EU MDR certification in May 2026. The financing release says the product has reached more than 700 medical-aesthetic clinics in China. A separate brand anniversary release reported nearly 150,000 syringes delivered during the first year. These are company-reported operating figures, not independently verified market-share data.
One investment does not establish that the CaHA regenerative-aesthetics market has completed its global expansion, nor does it prove that one technical approach is superior. It is more useful as a case study in what happens after registration and initial commercialization: competition expands to international market access, manufacturing continuity, supply-chain control, and platform development.
Why This Investment Matters to Materials Suppliers
The Cathay Consumer Co-Creation Fund was jointly established by the Shanghai Jing'an District Government, L'Oréal, and Cathay Capital. Its stated scope includes science-driven beauty, health and skin innovation, as well as the international growth of Chinese companies.
The fund therefore brings an industry-collaboration context to this transaction. That does not mean that “L'Oréal invested in CaHA,” or that investors have confirmed inevitable growth for the category. A more precise reading is that a CaHA company with key registrations and initial commercial reach has secured capital for its next stage of development.
The questions at that stage differ from those asked during early material development. An R&D program begins by asking whether a material can achieve the intended structure and function. Registration asks whether a finished product can be manufactured reproducibly and supported by a defined evidence package. Commercial scale adds another question: can larger volumes, more lots, and multiple regulatory regions remain comparable over time?
Feasibility, Product Registration, and Continuity of Supply
When CaHA powder or microspheres become part of an injectable product, they must be assessed together with the carrier, particle concentration, dispersion state, rheology, extrusion, sterilization, packaging, and manufacturing process. A strong laboratory sample is not automatically a sustainable commercial product.
| Stage | Materials and manufacturing questions |
|---|---|
| R&D validation | What is the CaHA phase? What are the microsphere size, morphology, surface, and pore structure? |
| Registration and design definition | Are test methods fixed? How are particles, carrier, and the complete formulation evaluated? Do sterilization and packaging preserve the expected state? |
| Scale-up and internationalization | Are scale-up lots comparable? Are trend data stable? How are material, equipment, and process changes assessed and communicated? |
At later stages, a single SEM image or particle-size value is no longer enough. Commercial supply depends on alignment among material data, manufacturing records, and the quality system.
A Finished-Product Registration Does Not Make All CaHA Raw Materials Equivalent
Public information describes Aphranel as a complete injectable system containing CaHA microspheres in a CMC gel carrier. Its regulatory, clinical, and commercial information applies to that specific finished product and manufacturing system.
Class III registration in China or EU MDR certification for the finished product does not give an upstream CaHA powder or microsphere the same regulatory status. It also does not establish equivalent performance for other CaHA raw materials.
As a finished product enters more demanding lifecycle management, its manufacturer will typically set clearer supply-chain expectations for critical-material origin, test methods, lot consistency, and change control. The manufacturer needs to know where a material comes from, how it is tested, whether lots are comparable, and which validated attributes may be affected by a manufacturing change.
An earlier article on this site discusses the regulatory context of Aphranel's EU MDR certification. The financing is better understood here through subsequent commercialization and supply-chain capability, rather than as another interpretation of the certificate itself.
Beyond 25–45 μm, Purchasing Language Becomes More Specific
As a development program moves toward routine supply, a material name and a stated size range must be converted into executable acceptance criteria.
For example, a requirement for “25–45 μm CaHA microspheres” still needs to define:
- whether 25–45 μm is a sieve window, an image-analysis interval, or a range reported by another particle-size method;
- how particles outside the range, fragments, and attached particles are counted;
- which methods assess sphericity, surface features, and internal structure;
- how XRD phase, Ca/P, and impurities are reported;
- whether microspheres remain intact after sterilization or formulation processing; and
- how changes to test methods, raw materials, or manufacturing processes are evaluated.
This does not mean that every product should use the same specifications. It means that the specification must match the material form, formulation design, and intended use. See 25–45 μm CaHA Microspheres: Specifications and Lot Acceptance for a more detailed purchasing framework.
Our View: Standardize the Material Foundation, Differentiate Application Specifications
From an upstream perspective, a mature CaHA industry does not require one universal microsphere for every program.
Phase identity, composition, impurity control, and core test methods need a stable foundation. Microsphere size, solid or porous structure, surface state, carrier compatibility, and downstream processing requirements may differ by product design. That is the difference between standardizing the material foundation and differentiating application specifications.
Both are necessary. Customization without stable baseline controls makes lots difficult to compare. A single standard specification without an understanding of the downstream system may fail to answer the real development question.
A supplier's long-term capability is therefore reflected in four areas:
- translating a customer's needs into testable material specifications;
- providing lot data and trend records using stable methods;
- keeping the evidence boundaries clear among powder, formed microspheres, and the complete formulation; and
- communicating material, equipment, and process changes in a timely and traceable way.
Nanjing Junzhuo can discuss particle-size definitions, microsphere structure, sample evaluation, and lot documentation for HAp/CaHA powders and CaHA microsphere materials. Final specifications should be defined around the formulation design, processing route, and validation goals of each program.
That is closer to the needs of commercial scale than demonstrating only that CaHA can be manufactured. For the distinction among material levels, see CaHA Powder, Microspheres, and Injectable Systems. For manufacturing changes, see CaHA Particle Manufacturing: Process Changes and Quality Control.
What the Investment Shows, and What It Does Not
The investment shows that a CaHA company with registrations and initial commercial reach can attract capital with international-growth and industry-collaboration objectives. MOYOM has also stated that its next phase extends beyond domestic launch to additional approvals, overseas markets, and development of a broader biomaterials platform.
It does not, by itself, establish category size, growth rate, clinical superiority, or investment returns. Nor does it make different CaHA microspheres, carriers, and finished products equivalent. Those conclusions require independent market data, product-specific evidence, and a longer commercial record.
The more durable signal for upstream suppliers is that global commercialization raises the value of clear specifications, consistent lots, traceable documentation, and controlled manufacturing changes. The next step for commercial CaHA is not simply to increase volume. It is to make material supply continuously verifiable.
This article is an industry analysis based on company releases, government information, and brand disclosures. Sales, clinic coverage, technology-platform, and market-planning figures are self-reported and do not constitute an independent assessment of product effectiveness, market share, company value, or investment prospects. Nanjing Junzhuo supplies upstream CaHA/HAp materials and supports custom development; it does not sell the finished injectable product discussed here.
References
- MOYOM Biotech. MOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aesthetics. September 28, 2026. PR Newswire.
- Shanghai Jing'an District Government. Cathay Consumer Co-Creation Fund Established to Support High-Quality Development of China's Beauty and Skincare Industry. April 2, 2025. Government page.
- Aphranel. Aphranel Receives EU MDR Certification for Its CaHA Facial Filler. May 18, 2026. Brand disclosure.
- Aphranel. First-Anniversary Update: Nearly 150,000 Syringes Delivered and EU MDR Certification. May 20, 2026. Brand disclosure.